Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
Parissis
John T
JT
Farmakis
Dimitrios
D
Kremastinos
Dimitrios T
DT
D002097:C-Reactive Protein / Q000032:analysis / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006835:Hydrazones / Q000494:pharmacology / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D020097:Natriuretic Peptide, Brain / Q000097:blood / Q000187:drug effects; D011724:Pyridazines / Q000494:pharmacology / Q000627:therapeutic use*; D000077464:Simendan; D013997:Time Factors; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D006835:Hydrazones; D015850:Interleukin-6; D011724:Pyridazines; D020097:Natriuretic Peptide, Brain; D000077464:Simendan; D002097:C-Reactive Protein